Hydrogen's Feasibility and Safety as a Therapy in ECPR

The purpose of this project is to test the feasibility and safety of inhaled hydrogen gas (H2) administration as a rescue therapy during cardiac arrest requiring extracorporeal cardiopulmonary resuscitation (ECPR, i.e. mechanical circulatory support). Under exemption from informed consent, patients undergoing refractory cardiac arrest in the cardiac ICU at a participating center will be randomized to standard therapy with or without the administration of 2% hydrogen in gases administered via the ventilator and ECMO membrane for 72 hours.

NCT Number	NCT05574296
Lead Sponsor	Boston Children's Hospital
Conditions	Cardiac Arrest, Extracorporeal Membrane Oxygenation, Reperfusion Injury
Enrollment	53 participants
Start Date	2024-03-04
Primary Completion	2027-03-31 (estimated)
Study Completion	2027-08-31 (estimated)
Updated on ClinicalTrials.gov	2025-07-03